The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index.
Alzheimer’s disease and gut microbiota modifications: The long way between preclinical studies and clinical evidence
Abstract
Recent studies have suggested the role of an infectious component in the pathogenesis of Alzheimer's disease (AD). In light of this, research has focused on some bacteria constituting the intestinal microbial flora which can produce amyloid. Once generated, the latter hypothetically triggers a systemic inflammatory response which compromises complex brain functions, such as learning and memory. Clinical studies have shown that, in cognitively impaired elderly patients with brain amyloidosis, there is lower abundance in the gut of E. rectale and B. fragilis, two bacterial species which have an anti-inflammatory activity, versus a greater amount of pro-inflammatory genera such as Escherichia/Shigella. According to these findings, some clinical studies have demonstrated that supplementation with Lactobacilli- and Bifidobacteria- based probiotics has improved cognitive, sensory and emotional functions in subjects with AD. Moreover, certain herbal products, in particular dietetic polyphenols, have proved capable of restoring dysbiosis and, therefore, their prebiotic role could be effective in counteracting the onset of AD regardless of their activity of free radical scavenging or enhancement of the cell stress response. One of the recent greatest novelties in the field of neurodegenerative diseases is the chance to prevent or slow down AD progression with agents, such as probiotics and prebiotics, acting outside the central nervous system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the stools of patients with AD, the abundance of pro-inflammatory bacteria (Escherichia/Shigella) increases and the abundance of anti-inflammatory bacteria (Eubacterium rectale) and Bacteroides fragilis decreases (Mancuso and Santangelo 2018).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Mancuso and Santangelo 2018
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
2013 Alzheimer's disease facts and figures
Thies, W. H., & Bleiler, L. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,365
Flagged first, then by citations
1 of the 108 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–233 of 233
Shah, F., & Dwivedi, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-6760-2_4 · Cited by 1
Gut microbiota: a new insight into neuropsychiatric disorders
Liu, L., Wang, H., & Xie, P. (2022) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0325 · Cited by 1
DEVELOPMENT OF FUNCTIONAL BEVERAGES ON THE BASE OF WHEY
Saubenova, M., msaubenova@mail.ru, & Oleinikova, Y. (2018) · SERIES OF BIOLOGICAL AND MEDICAL · doi:10.32014/2018.2518-1629.5 · Cited by 1
Neuro-inflammation dans les maladies neurologiques. Rôle des probiotiques
Joffre, C., Dinel, A., & Layé, S. (2018) · Phytothérapie · doi:10.3166/phyto-2018-0093
You, Q., Wang, W., Tao, T., Wang, T., Zhang, D., & Wang, L. (2022) · Journal of Biomaterials and Tissue Engineering · doi:10.1166/jbt.2022.2959
Human Microbiome and the Neurological Disorders
Pamanji, R., & Selvin, J. (2023) · Springer eBooks · doi:10.1007/978-981-99-1463-0_8
Muralidhara, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19084-1.00015-6 · Cited by 1
Song, J., Li, M., Kang, N., Jin, W., Xiao, Y., Li, Z., Qi, Q., Zhang, J., Duan, Y., Feng, X., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3302159/v1
Role of probiotics in brain health
Thakur, A. K., Shekhar, N., Tyagi, S., & Rani, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18951-7.00009-8
Bilirubin Nanomedicines for the Treatment of Reactive Oxygen Species (ROS)-Mediated Diseases
Gupta, Y., Shikha, R., Rai, V., Bano, N., Khan, S., & Yadav, R. (2024) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.3.1.25
“Recent advancements in nanomedicine have opened avenues for harnessing the therapeutic potential of bilirubin in a targeted and controlled manner(3).”
BackgroundIntroduction to Gut Microbiota and their Effects on Various Brain Disorders
Usmani, A., & Mishra, A. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815238754124010008
Role of the Gut Microbiome and Bacterial Amyloids in the Development of Synucleinopathies (Review)
Trubitsina, N. P., Matiiv, A. B., Rogoza, T. M., Zudilova, A. A., Bezgina, M. D., Zhouravleva, G. A., & Bondarev, S. A. (2024) · Biochemistry (Moscow) · doi:10.31857/s0320972524030089
Gut-Brain Axis: Probiotics as Psychobiotics
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_16
The gut-microbiota and neurodegenerative disorders: What is the interplay?
Aljumayi, H., Khalil, N. A., & Alrasheedi, A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00006-3
Future prospective of microbiome-gut brain axis for treatment of CNS disorders
Mane, R., Kashid, S., Mazahir, F., & Yadav, A. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21680-0.00019-5
Devi, U., Ganguly, R., Verma, Y. K., & Shukla, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29932-2.00007-4
The Effect of Probiotics on Mental Health
Yılmaz, G. G. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-1414-4_12
Cognitive dysfunction resulting in telomere degradation: the potential of probiotics as a supplement
Sekar, J. M., Prabhu, V., Subramanian, P., Nehru, M., & Subbiah, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27622-4.00002-x
Phytopharmaceuticals and the Gut-Brain Axis in Neurodegenerative Therapy
Kharl, H. A. A., Mehreen, A., Gillani, Q.-U.-A., Afzal, A., Shakoor, F., Siddique, A., Taqi, M. H., & Farooq, A. B. B. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-4139-2.ch008
Sahoo, S., Dewangan, S., Dubey, D., Sahu, P. K., Kar, D. M., Sahoo, J., Tiwle, R., & Prusty, S. K. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00122
Exploration du microbiote digestif par des approches multi-OMICS
Ngom, I. I. (2019) · theses.fr (ABES) · doi:10.70675/5cd8042ezb909z42b5z9024z3cb428057fe3
Tang, Z., Yang, J., Guo, X., Hao, Z., Wang, H., Ommati, M. M., & Yuan, J. (2026) · NeuroToxicology · doi:10.1016/j.neuro.2026.103498
Das, K., Khatun, R., Begum, S., Bhattacharyya, K., Datta, M., Saha, D., Sarma, A., Mehta, P., & Das, B. K. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01922-9
“The importance of intestinal microbiota has contributed to a clearer understanding of the disease mechanism of AD (Mancuso and Santangelo 2018).”
Jia, W., Zhou, Z., Chen, H., Pu, J., Yang, M., Yang, T., 簡瑞霖, He, F., & Cheng, R. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106883
Zi, Y., Zhang, J., Lu, C., Pan, B., Zhao, X., & Xiao, X. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109395
Neonatal predictors of neurodevelopment: the interplay between APGAR score and neonatal microbiome
parthiban, R., Bhavya, E., Shireen, S. M., & Solomon, J. A. J. (2026) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-026-04498-6 · Cited by 1
Gut Microbiome Changes in Preclinical Alzheimer’s Disease
Dissanayaka, S. U., Rainey‐Smith, S. R., Sohrabi, H. R., Jayasinghe, T. N., Ho, V., Jayasena, V., Taddei, K., Masters, C. L., Martins, R. N., & Fernando, W. M. A. D. B. (2026) · Nutrients · doi:10.3390/nu18152469 · Cited by 1
“…gut microbial composition, functional pathways, and metabolite production during the pre-clinical stage may provide critical insight into early biological changes associated with AD and help clarify the potential role of the gut microbiome in disease initiation and progression [121,145,146].”
Chen, Y., Ho, C., & Zhang, X. (2026) · Food Research International · doi:10.1016/j.foodres.2026.120579
Han, Z., Chen, H., Yao, Y., Bo, X., Ni, X., Liu, H., Bai, M., Li, T., Bao, L., Zhang, D., et al. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06144-9
“…shown common features such as extensive deposition of β-amyloid protein (Aβ) outside brain neurons, forming senile plaques; hyperphosphorylation of tau protein, leading to the formation of intracellular neurofibrillary tangles; neuronal loss; neurotrophic deficiencies; and synaptic loss [6, 7].”
Zhu, W., Tang, R., Wu, F., Yi, L., Ouyang, Y., & Zhang, Z. (2026) · Carbohydrate Research · doi:10.1016/j.carres.2026.110126
BindingDB Entry 50016861: DYRK1A inhibitors for disease therapy: Current status and perspectives.
BindingDB (2023) · UC San Diego · doi:10.7270/q2pv6qds
Metadata
- Authors
- Mancuso, C., & Santangelo, R.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Mancuso, Cesare
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 129
- Pages
- 329-336
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2774851697
- Cited by
- 232
- References
- 108
- Citations by year
- 2026: 21 · 2025: 29 · 2024: 30 · 2023: 25 · 2022: 29 · 2021: 27 · 2020: 28 · 2019: 23 · 2018: 20
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacological Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Catholic University
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- Alzheimer's disease, gut microbiota, gut-brain axis, amyloid, Bacteroides fragilis, lactobacilli, Bifidobacterium, probiotics, prebiotics, polyphenols, dysbiosis, neuroinflammation, cognitive impairment, neurodegeneration
- MeSH terms
- Gastrointestinal Microbiome, Aging, Alzheimer Disease, Animals, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
